Reyes-López A, Guillen J

Language: Spanish
References: 13
Page: 107-114
PDF size: 408.46 Kb.

ABSTRACT

Objective: To perform a cost-effectiveness analysis of irbesartan from the perspective of patients in Honduras. Material and methods. Efficacy data was obtained from clinical trials where irbesartan was compared to other antihypertensive drugs of the same therapeutic class. Prices of medicines were obtained from a survey to the main chains of pharmacies in the country. A probabilistic sensitivity analysis was conducted to assess the impact of variations in prices on the results. Results. Irbesartan resulted a dominant treatment option since it was more effective and less costly. The sensitivity analysis revealed an important effect of price variations on the cost-effectiveness results. Discussion. Currently the choice of treatments should not be based purely on financial criteria or based only on clinical information. Pharmacoeconomics allows decision-makers to choose therapies based on efficiency criteria.

REFERENCES

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.

2. Disponible en_ http://new.paho.org/hon/index.php? option=com_joomlabook&Itemid=259&task=display&id=221 [Consultado el 22 de diciembre 2010].

3. Elliot WJ. The economic impact of hypertension. J Clin Hypertension 2003; 5(3 Suppl. 2): 3-13.

4. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales? Rev Esp Cardiol Supl 2006; 6: 10C-24C.

5. Malacco E, Piazza S, Meroni R, Milanesi A. Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study. Current Therapeutic Research 2006; 1(11): 789-97.

6. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7(2): 135-42.

7. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmaret R. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18(11): 1482-8.

8. Fogari R, Mugellini A, Zoppi A, Fogari E, Marasi G, Pesce RM, Banderali A. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. Current Therapeutic Research 2000; 61(10): 669-79.

9. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/ hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005; 33: 620-31.

10. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistance hypertensive patients. J Endocrinol Invest 2006; 29: 957-61.

11. Coca A. Importancia del control de la presión arterial sistólica en la reducción del riesgo vascular. Nefrología 2002; 22(Supl. 2): 44-5.

12. Prieto L, Sacristán JA, Antoñanzas F, Rubio-Terrés C, Pinto JL, Rovira J. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Med Clin (Barc) 2004; 122(13): 505-10.

13. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311: 485.